Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · IEX Real-Time Price · USD
38.24
-0.34 (-0.88%)
At close: May 17, 2024, 4:00 PM
36.56
-1.68 (-4.39%)
After-hours: May 17, 2024, 5:43 PM EDT
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $42.56M in the twelve months ending March 31, 2024, with 53.22% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $27.61M with 1,004.56% year-over-year growth. In the year 2023, Tarsus Pharmaceuticals had annual revenue of $17.45M, a decrease of -32.42%.
Revenue (ttm)
$42.56M
Revenue Growth
+53.22%
P/S Ratio
34.13
Revenue / Employee
$174,430
Employees
244
Market Cap
1.45B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
Dec 31, 2021 | 57.03M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.42B |
Brookdale Senior Living | 3.05B |
Omnicell | 1.10B |
Pacira BioSciences | 681.75M |
Kiniksa Pharmaceuticals | 301.77M |
Maravai LifeSciences Holdings | 274.10M |
Dynavax Technologies | 236.15M |
Xencor | 162.18M |
TARS News
- 9 days ago - Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference - GlobeNewsWire
- 10 days ago - Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements - GlobeNewsWire
- 17 days ago - Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 - GlobeNewsWire
- 25 days ago - Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon - GlobeNewsWire
- 2 months ago - Tarsus to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis - GlobeNewsWire
- 2 months ago - Tarsus Announces Pricing of $100.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Tarsus Announces Proposed $100.0 Million Public Offering - GlobeNewsWire